LINC00963 Promotes Cancer Stemness, Metastasis, and Drug Resistance in Head and Neck Carcinomas via ABCB5 Regulation.
ABCB5
LINC00963
cancer stemness
chemoresistance
head and neck
lncRNA
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
26 Apr 2020
26 Apr 2020
Historique:
received:
14
02
2020
revised:
10
04
2020
accepted:
20
04
2020
entrez:
3
5
2020
pubmed:
3
5
2020
medline:
3
5
2020
Statut:
epublish
Résumé
Accumulating studies have indicated that long non-coding RNAs (lncRNAs) participate in the regulation of cancer stem cells (CSCs), which are crucial in tumor initiation, metastasis, relapse, and therapy resistance. In the current study, RT-PCR analysis was employed to evaluate the expression of LINC00963 in tumor tissues and oral CSCs. Stemness phenotypes and the expression of CSCs markers in oral cancer cells transfected with sh-LINC00963 were examined. Our results showed that the expression of the lncRNA LINC00963 was up-regulated in oral cancer tissues and CSCs. We found that the downregulation of LINC00963 inhibited CSC hallmarks, such as migration, invasion and colony formation capacity. Moreover, suppression of LINC00963 reduced the activity of stemness marker ALDH1, the percentage of self-renewal, chemoresistance and the expression of multidrug-resistance transporter ABCB5. Most importantly, we demonstrated that knockdown of LINC00963 decreased self-renewal, invasion and colony formation ability via ABCB5. Analysis of TCGA (the Cancer Genome Atlas) datasets suggested that the level of LINC00963 was positively correlated with the expression of the cancer stemness markers (Sox2 and CD44) and drug resistance markers (ABCG2 and ABCB5). Altogether, our results showed that suppression of LINC00963 may be beneficial to inhibit chemoresistance and cancer relapse in oral cancer patients.
Identifiants
pubmed: 32357409
pii: cancers12051073
doi: 10.3390/cancers12051073
pmc: PMC7281373
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
Mol Ther Nucleic Acids. 2019 Dec 6;18:871-881
pubmed: 31751910
Cancer Lett. 2018 May 1;421:121-126
pubmed: 29331418
Cancer Res. 2017 Nov 1;77(21):5782-5794
pubmed: 28923857
Cell Cycle. 2020 Mar;19(5):610-624
pubmed: 32052688
Gastroenterology. 2011 Jan;140(1):344-55
pubmed: 20682318
Int J Oncol. 2014 Jun;44(6):2041-9
pubmed: 24691949
Proc Natl Acad Sci U S A. 2007 Jan 16;104(3):973-8
pubmed: 17210912
J Formos Med Assoc. 2017 Jan;116(1):41-48
pubmed: 26879838
Cancers (Basel). 2018 Aug 16;10(8):
pubmed: 30115848
J Dent Res. 2012 Apr;91(4):334-40
pubmed: 21933937
Front Oncol. 2019 Jul 25;9:669
pubmed: 31404273
J Oral Pathol Med. 2009 Sep;38(8):657-62
pubmed: 19563504
J Oral Pathol Med. 2011 Sep;40(8):621-8
pubmed: 21342274
Stem Cell Rev Rep. 2018 Dec;14(6):769-784
pubmed: 30076557
J Biol Chem. 2003 Nov 21;278(47):47156-65
pubmed: 12960149
Oncotarget. 2017 Jan 17;8(3):4196-4207
pubmed: 27926533
Int J Cancer. 2015 Mar 1;136(5):E359-86
pubmed: 25220842
J Biol Chem. 2018 Jul 13;293(28):11166-11178
pubmed: 29789423
Oral Oncol. 2010 Jan;46(1):49-55
pubmed: 20005769
Stem Cells. 2013 Apr;31(4):641-51
pubmed: 23355370
Cancer Res. 2005 May 15;65(10):4320-33
pubmed: 15899824
Eur Rev Med Pharmacol Sci. 2020 Jan;24(1):164-173
pubmed: 31957829
J Pathol. 2011 Mar;223(4):482-95
pubmed: 21294122
Acta Odontol Scand. 2015 Jul;73(5):336-42
pubmed: 25234444
Cancer Res. 2011 Aug 1;71(15):5307-16
pubmed: 21652540
Eur J Cancer. 2012 Nov;48(17):3186-97
pubmed: 22784549
Head Neck. 2010 Sep;32(9):1195-201
pubmed: 20073073
Biochem Biophys Res Commun. 2012 Feb 24;418(4):736-41
pubmed: 22306008
Cancer Res. 2014 Aug 1;74(15):4196-207
pubmed: 24934811
Int J Biochem Cell Biol. 2019 Mar;108:17-20
pubmed: 30630112
Clin Cancer Res. 2008 Jul 1;14(13):4085-95
pubmed: 18593985